CD28 and graft versus host disease: Combination therapies with agents that target other pathways such as CD28:CD80/86 constimulation with abatacept (89), Rho-associated kinase 2 with belumosudil (90), or CSF-1R blockade with axatilimab (91) may also prove beneficial as we refine our understanding of the pathogenic pathways controlling development of GVHD.